Rohto Pharmaceutical Co (FRA:UC1) Other Financing: €0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UC1 Rohto Pharmaceutical Co Ltd FRA:UC1
73 GF Score
Price €12.90
GF Value €18.58
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Rohto Pharmaceutical Co Other Financing?

Rohto Pharmaceutical Co FRA:UC1 -1.53% 73 Other Financing is €0 Mil as of Mar. 2026. GuruFocus rates FRA:UC1 with a GF Score™ of 73/100 and a GF Value™ of €18.58 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Rohto Pharmaceutical Co's Other Financing for the three months ended in Mar. 2026 was €0 Mil.

Rohto Pharmaceutical Co's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Rohto Pharmaceutical Co Other Financing Historical Data

* Premium members only.

The historical data trend for Rohto Pharmaceutical Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rohto Pharmaceutical Co Other Financing Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.35 -11.47 -43.51 112.38 -0.02

Rohto Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:UC1
73GF Score
Rohto Pharmaceutical Co Ltd FRA:UC1
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rohto Pharmaceutical Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0 Mil mean?
Rohto Pharmaceutical Co (FRA:UC1) has a Other Financing of €0 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Rohto Pharmaceutical Co and its competitors.
Is Rohto Pharmaceutical Co's Other Financing too high?
Rohto Pharmaceutical Co's current Other Financing is €0 Mil. Overall, Rohto Pharmaceutical Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Other Financing compare to PG and CL?
Rohto Pharmaceutical Co's Other Financing of €0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Consumer Packaged Goods company?
A good Other Financing depends on the Consumer Packaged Goods industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Rohto Pharmaceutical Co and its competitors. Rohto Pharmaceutical Co's current Other Financing is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (FRA:UC1) is currently considered Significantly Undervalued. The stock's GF Value™ is €18.58, compared to a current price of €12.90 — trading 30.6% below its estimated fair value. The current Other Financing is €0 Mil. Rohto Pharmaceutical Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Rohto Pharmaceutical Co (FRA:UC1), the current Other Financing is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rohto Pharmaceutical Co (FRA:UC1) Overvalued in 2026?

Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued. The current stock price of €12.90 is trading 30.6% below its estimated GF Value™ of €18.58. GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for FRA:UC1:

  • Other Financing: €0 Mil
  • GF Value™: €18.58 vs. price of €12.90 (30.6% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the FRA:UC1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rohto Pharmaceutical Co Business Description

Other Exchanges RPHCF:USA4527:Japan
Address 1-8-1 Tatsuminishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
73GF Score

Get the complete analysis for FRA:UC1

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.90
Price
€18.58
GF Value